EGFR and non-small cell lung carcinoma: Clinical studies in patients with NSCLC have explored the feasibility of EGFR mutation detection using cfDNA from serum and/or plasma samples, as well as the prognostic value and potential utility of EGFR mutation positivity by cfDNA to predict clinical outcomes to EGFR-targeted therapies (Kimura et al, 2006, 2007; Bai et al, 2009; He et al, 2009; Brevet et al, 2011; Lee et al, 2011; Goto et al, 2012; Mok et al, 2013; Li et al, 2014; Douillard et al, 2014a, 2014b; Mok et al, 2015).